This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Filgotinib for moderately to severely active ulcerative colitis

< Back

Filgotinib for moderately to severely active ulcerative colitis


Gastrointestinal, Pancreatic and Liver Disease

November 2019

Filgotinib is in clinical development for the treatment of patients with moderately to severely active ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and ulcers in the bowel and rectum which can cause diarrhoea, abdominal pain and faecal urgency or incontinence. The symptoms of ulcerative colitis often follow a pattern of relapse and remission where they have periods of none or mild symptoms followed by periods of increased symptoms flare-up (‘active’). There are no curative therapies for ulcerative colitis and current treatment aims to relieve symptoms during a flare-up and maintain remission by preventing symptoms from returning.
Filgotinib is administered orally in tablet form. It works by binding to and blocking a pathway of the JAK enzymes, which mediates the signalling and activity of many molecules involved in inflammation and immune mediated diseases. Filgotinib is highly selective for JAK1 so it may have fewer adverse effects compared to other non-selective drugs that block all JAK enzymes. If licensed, filgotinib will offer an additional treatment option for the induction and maintenance of remission in adults with moderately to severely active ulcerative colitis.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts